Evaxion Biotech A/S (NASDAQ:EVAX) Sees Significant Growth in Short Interest

Evaxion Biotech A/S (NASDAQ:EVAX) saw a large growth in short interest in the month of January. As of January 15th, there was short interest totalling 980,100 shares, a growth of 709.3% from the December 31st total of 121,100 shares. Based on an average daily trading volume, of 335,500 shares, the short-interest ratio is presently 2.9 days.

Institutional Trading of Evaxion Biotech A/S

An institutional investor recently bought a new position in Evaxion Biotech A/S stock. Invst LLC bought a new stake in Evaxion Biotech A/S (NASDAQ:EVAX) in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 54,000 shares of the company’s stock, valued at approximately $156,000. Invst LLC owned approximately 1.00% of Evaxion Biotech A/S as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 11.04% of the company’s stock.

Evaxion Biotech A/S Stock Down 27.2 %

EVAX opened at $4.37 on Wednesday. Evaxion Biotech A/S has a 1 year low of $2.38 and a 1 year high of $36.90. The firm has a 50 day moving average price of $5.25 and a 200 day moving average price of $11.01. The company has a debt-to-equity ratio of 7.99, a quick ratio of 2.80 and a current ratio of 1.00. The company has a market cap of $5.11 million, a PE ratio of -3.01 and a beta of -0.23.

Evaxion Biotech A/S (NASDAQ:EVAX) last released its quarterly earnings data on Thursday, October 31st. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.60) by $0.40. The business had revenue of $3.02 million during the quarter, compared to analyst estimates of $0.19 million. Sell-side analysts expect that Evaxion Biotech A/S will post -0.43 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $70.00 target price on shares of Evaxion Biotech A/S in a research report on Friday, November 1st.

Evaxion Biotech A/S Company Profile

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.